Velikova M, Tsvekova V, Koĭnov K
Akush Ginekol (Sofiia). 1993;32(1):23-5.
The study is prospective and includes 72 patients. All the patients are subjected to surgical treatment--total hysterectomy with bilateral adnexectomy and partial or total omentectomy and all of them are without macroscopic metastases in the abdominal cavity. Adjuvant chemotherapy includes from 3 to 5 courses of combination chemotherapy with platinum preparation (Bio-cisplatinum) in intervals of 30 days. Seven out of 72 studied patients (9.7%) have shown recurrence of the neoplastic disease. These patients are in stage II and III. Four of them are at age below 50 years, while the other 3--over 50. With the greatest relative part are the recurrent patients with granulosa cell cancer--33%, followed by the patients with mixed histologic type--25%, with mesonephric cancer--17% and papillary cystadenocarcinoma--10%. Regardless the small number of patients in the different groups, a tendency is outlined for a better therapeutic results after application of adjuvant chemotherapy in sensitive to cytostatic treatment histologic types of ovarian cancer. The disease free interval and the survival prolong, especially in II and III stage patients. Better therapeutic results are achieved by application of 5 courses of platinum including chemotherapy than by the application of 3 courses.
该研究为前瞻性研究，包括72例患者。所有患者均接受手术治疗——全子宫切除加双侧附件切除及部分或全部大网膜切除，且所有患者腹腔内均无肉眼可见转移灶。辅助化疗包括3至5个疗程的铂类制剂（生物顺铂）联合化疗，疗程间隔为30天。72例研究患者中有7例（9.7%）出现肿瘤疾病复发。这些患者处于II期和III期。其中4例年龄在50岁以下，另外3例年龄在50岁以上。复发患者中颗粒细胞癌占比最大——33%，其次是混合组织学类型患者——25%，中肾细胞癌患者——17%，乳头状囊腺癌患者——10%。尽管不同组的患者数量较少，但对于对细胞抑制治疗敏感的组织学类型的卵巢癌患者，应用辅助化疗后有治疗效果更好的趋势。无病间期和生存期延长，尤其是II期和III期患者。应用5个疗程含铂化疗比应用3个疗程能取得更好的治疗效果。
